Immune system cancer drugs tipped to be a $35 billion market

A new wave of medicines that tap the power of the immune
system to fight cancer could become the biggest drug class in history, with
potential sales of $35 billion a year. That bullish sales forecast by analysts at U.S. bank Citigroup highlights the growing excitement surrounding so-called immunotherapy after positive results from clinical trials conducted by companies such as Bristol-Myers
Squibb and Roche Holding. Read here more.